<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title> • RE-Test-Reports</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet">
<link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet">
<script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="">
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">RE-Test-Reports</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.0.0.9000</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-reports" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Reports</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-reports">
<li><a class="dropdown-item" href="../articles/Aciclovir-Mean.html">Aciclovir-Mean</a></li>
    <li><a class="dropdown-item" href="../articles/Aciclovir-Mean-SVG.html">Aciclovir-Mean-SVG</a></li>
    <li><a class="dropdown-item" href="../articles/Aciclovir-Population.html">Aciclovir-Population</a></li>
    <li><a class="dropdown-item" href="../articles/Raltegravir-Absorption.html">Raltegravir-Absorption</a></li>
    <li><a class="dropdown-item" href="../articles/Raltegravir-Mass-Balance.html">Raltegravir-Mass-Balance</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO7.html">Test-NO7</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO8.html">Test-NO8</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO9.html">Test-NO9</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO10.html">Test-NO10</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO11.html">Test-NO11</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO12.html">Test-NO12</a></li>
  </ul>
</li>
<li class="active nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-qualification-reports" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Qualification Reports</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-qualification-reports">
<li><a class="dropdown-item" href="../articles/Qualification-CKD.html">Qualification-CKD</a></li>
    <li><a class="dropdown-item" href="../articles/Qualification-HI.html">Qualification-HI</a></li>
    <li><a class="dropdown-item" href="../articles/Pediatric_Qualification_Package_UGT1A1_Ontogeny.html">Pediatric_Qualification_Package_UGT1A1_Ontogeny</a></li>
    <li><a class="dropdown-item" href="../articles/Digoxin-Model.html">Digoxin-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Propofol-Model.html">Propofol-Model</a></li>
    <li><a class="dropdown-item" href="../articles/dAb2-Model.html">dAb2-Model</a></li>
    <li><a class="dropdown-item" href="../articles/MEDI524YTE-Model.html">MEDI524YTE-Model</a></li>
    <li><a class="dropdown-item" href="../articles/MEDI524-Model.html">MEDI524-Model</a></li>
    <li><a class="dropdown-item" href="../articles/7E3-Model.html">7E3-Model</a></li>
    <li><a class="dropdown-item" href="../articles/CDA1-Model.html">CDA1-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Inulin-Model.html">Inulin-Model</a></li>
    <li><a class="dropdown-item" href="../articles/BAY794620-Model.html">BAY794620-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Tefibazumab-Model.html">Tefibazumab-Model</a></li>
    <li><a class="dropdown-item" href="../articles/TestInput01_DDI.html">TestInput01_DDI</a></li>
  </ul>
</li>
      </ul>
<ul class="navbar-nav">
<li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json">
</form></li>
      </ul>
</div>


  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1></h1>
            
      

      <div class="d-none name"><code>Propofol-Model.Rmd</code></div>
    </div>

    
    
<div class="section level2">
<h2 id="building-and-evaluation-of-a-pbpk-model-for-propofol-in-adults">Building and evaluation of a PBPK model for propofol in adults<a class="anchor" aria-label="anchor" href="#building-and-evaluation-of-a-pbpk-model-for-propofol-in-adults"></a>
</h2>
<table class="table">
<colgroup>
<col width="43%">
<col width="56%">
</colgroup>
<thead><tr class="header">
<th>Version</th>
<th>1.0-OSP11.0</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>based on <em>Model Snapshot</em> and <em>Evaluation Plan</em>
</td>
<td><a href="https://github.com/Open-Systems-Pharmacology/Propofol-Model/releases/tag/v1.0" class="external-link uri">https://github.com/Open-Systems-Pharmacology/Propofol-Model/releases/tag/v1.0</a></td>
</tr>
<tr class="even">
<td>OSP Version</td>
<td>11.0</td>
</tr>
<tr class="odd">
<td>Qualification Framework Version</td>
<td>3.0</td>
</tr>
</tbody>
</table>
<p>This evaluation report and the corresponding PK-Sim project file are
filed at:</p>
<p><a href="https://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library/" class="external-link uri">https://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library/</a></p>
</div>
<div class="section level2">
<h2 id="table-of-contents">Table of Contents<a class="anchor" aria-label="anchor" href="#table-of-contents"></a>
</h2>
<ul>
<li><a href="#introduction">1 Introduction</a></li>
<li>
<a href="#methods">2 Methods</a>
<ul>
<li><a href="#modeling-strategy">2.1 Modeling strategy</a></li>
<li><a href="#data">2.2 Data used</a></li>
<li><a href="#model-parameters-and-assumptions">2.3 Model parameters and
assumptions</a></li>
</ul>
</li>
<li>
<a href="#results-and-discussion">3 Results and Discussion</a>
<ul>
<li><a href="#final-input-parameters">3.1 Propofol final input
parameters</a></li>
<li><a href="#diagnostics-plots">3.2 Propofol Diagnostics Plots</a></li>
<li><a href="#ct-profiles-model-building">3.3 Propofol
Concentration-Time profiles</a></li>
</ul>
</li>
<li><a href="#conclusion">4 Conclusion</a></li>
<li><a href="#references">5 References</a></li>
</ul>
</div>
<div class="section level2">
<h2 id="introduction">1 Introduction<a id="introduction"></a><a class="anchor" aria-label="anchor" href="#introduction"></a>
</h2>
<p>The presented model building and evaluation report evaluates the
performance of a PBPK model for propofol in adults.</p>
<p>Propofol is an anaesthetic agent used for induction and maintenance
of general anaesthesia. Propofol is only given intravenously and is
mainly metabolized by Uridine 5’-diphospho-glucuronosyltransferase 1A9
(UGT1A9) (53-70%) <a href="#id_5-references">(Al-Jahdari 2006, Restrepo
2009</a>). The final propofol model features metabolism by UGT1A9 and to
a minor extent by Cytochrome P450 2B6 (CYP2B6) <a href="#id_5-references">(Al-Jahdari 2006, Oda 2009</a>). Additionally,
there is excretion via glomerular filtration. The model adequately
describes the pharmacokinetics of propofol in adults.</p>
<p>The propofol model is a whole-body PBPK model, allowing for dynamic
translation between individuals with organs expressing UGT1A9. The
propofol report demonstrates the level of confidence in the propofol
PBPK model build with the OSP suite with regard to reliable predictions
of propofol PK adults during model-informed drug development.</p>
</div>
<div class="section level2">
<h2 id="methods">2 Methods<a id="methods"></a><a class="anchor" aria-label="anchor" href="#methods"></a>
</h2>
<div class="section level3">
<h3 id="modeling-strategy">2.1 Modeling strategy<a id="modeling-strategy"></a><a class="anchor" aria-label="anchor" href="#modeling-strategy"></a>
</h3>
<p>The general concept of building a PBPK model has previously been
described by Kuepfer et al. (<a href="#id_5-references">Kuepfer
2016</a>). Relevant information on anthropometric (height, weight) and
physiological parameters (e.g. blood flows, organ volumes, binding
protein concentrations, hematocrit, cardiac output) in adults was
gathered from the literature and has been previously published (<a href="#id_5-references">Schlender 2016</a>). The information was
incorporated into PK-Sim® and was used as default values for the
simulations in adults.</p>
<p>The applied activity and variability of plasma proteins and active
processes that are integrated into PK-Sim® are described in the publicly
available PK-Sim® Ontogeny Database Version 7.3 (<a href="#id_5-references">PK-Sim Ontogeny Database Version 7.3</a>) or
otherwise referenced for the specific process.</p>
<p>First, a base mean model was built using data from the single dose
escalation study to find an appropriate structure describing the PK of
propofol. The mean PK model was developed using a typical European
individual. Unknown parameters were identified using the Parameter
Identification module provided in PK-Sim®. Structural model selection
was mainly guided by visual inspection of the resulting description of
data and biological plausibility.</p>
<p>A final PBPK model was established and simulations were compared to
the reported data to evaluate model appropriateness and to assess model
qualification, by means of diagnostics plots and predicted versus
observed concentration-time profiles, of which the results support an
adequate prediction of the PK in adults.</p>
<p>During model building, uncertainties in data quality, as well as
study differences may cause not being able to adequately describe the PK
of all reported clinical studies.</p>
</div>
<div class="section level3">
<h3 id="data-used">2.2 Data used<a id="data"></a><a class="anchor" aria-label="anchor" href="#data-used"></a>
</h3>
<div class="section level4">
<h4 id="in-vitro-physicochemical-data">2.2.1 In vitro / physicochemical data<a class="anchor" aria-label="anchor" href="#in-vitro-physicochemical-data"></a>
</h4>
<p>A literature search was performed to collect available information on
physicochemical properties of propofol. The obtained information from
literature is summarized in the table below, and is used for model
building.</p>
<table class="table">
<colgroup>
<col width="13%">
<col width="9%">
<col width="34%">
<col width="41%">
</colgroup>
<thead><tr class="header">
<th align="left"><strong>Parameter</strong></th>
<th><strong>Unit</strong></th>
<th><strong>Literature value (reference)</strong></th>
<th><strong>Description</strong></th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">MW</td>
<td>g/mol</td>
<td>178.2707 (<a href="#id_5-references">Drugbank.ca</a>)</td>
<td>Molecular weight</td>
</tr>
<tr class="even">
<td align="left">pKa</td>
<td></td>
<td>10.1 (<a href="#id_5-references">Drugbank.ca</a>)</td>
<td>Acid dissociation constant</td>
</tr>
<tr class="odd">
<td align="left">Solubility (pH)</td>
<td>mg/L</td>
<td>124 (7) (<a href="#id_5-references">Drugbank.ca</a>)</td>
<td>Solubility</td>
</tr>
<tr class="even">
<td align="left">logP (pH 7)</td>
<td></td>
<td>0.58 (<a href="#id_5-references">Moss 2012</a>)</td>
<td>Partition coefficient between octanol and water</td>
</tr>
<tr class="odd">
<td align="left">fu</td>
<td></td>
<td>0.024 (<a href="#id_5-references">Takizawa 2005</a>)</td>
<td>Fraction unbound</td>
</tr>
<tr class="even">
<td align="left">Km,u UGT1A9</td>
<td>mM</td>
<td>0.12 (<a href="#id_5-references">Al-Jahdari 2006</a>)</td>
<td>Unbound Michaelis-Menten constant</td>
</tr>
<tr class="odd">
<td align="left">Vmax UGT1A9</td>
<td>nmol/min/mg</td>
<td>2.40 (<a href="#id_5-references">Al-Jahdari 2006</a>)</td>
<td>Maximum rate of reaction</td>
</tr>
<tr class="even">
<td align="left">Km,u CYP2B7</td>
<td>mM</td>
<td>0.03 (<a href="#id_5-references">Al-Jahdari 2006</a>)</td>
<td>Unbound Michaelis-Menten constant</td>
</tr>
<tr class="odd">
<td align="left">Vmax CYP2B7</td>
<td>nmol/min/mg</td>
<td>1.08 (<a href="#id_5-references">Al-Jahdari 2006</a>)</td>
<td>Maximum rate of reaction</td>
</tr>
</tbody>
</table>
</div>
<div class="section level4">
<h4 id="clinical-data">2.2.2 Clinical data<a class="anchor" aria-label="anchor" href="#clinical-data"></a>
</h4>
<p>A literature search was performed to collect available clinical data
on propofol in adults.</p>
<p>The following publications were used in adults for model building and
evaluation, of which individual patient data was available for download
under <a href="http://opentci.org/data/propofol" class="external-link uri">http://opentci.org/data/propofol</a>:</p>
<table class="table">
<colgroup>
<col width="35%">
<col width="64%">
</colgroup>
<thead><tr class="header">
<th align="left">Publication</th>
<th align="left">Study description</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left"><a href="#id_5-references">Gepts 1987</a></td>
<td align="left">Disposition of propofol administered as constant rate
intravenous infusion in humans</td>
</tr>
<tr class="even">
<td align="left"><a href="#id_5-references">Schnider 1998</a></td>
<td align="left">Influence of administration rate on propofol
plasma-effect site equilibrium</td>
</tr>
<tr class="odd">
<td align="left"><a href="#id_5-references">Struys 2007</a></td>
<td align="left">The influence of method of administration and
covariates on the pharmacokinetics of propofol in adult volunteers</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level3">
<h3 id="model-parameters-and-assumptions">2.3 Model parameters and
assumptions<a id="model-parameters-and-assumptions"></a><a class="anchor" aria-label="anchor" href="#model-parameters-and-assumptions"></a>
</h3>
<div class="section level4">
<h4 id="absorption">2.3.1 Absorption<a class="anchor" aria-label="anchor" href="#absorption"></a>
</h4>
<p>Propofol is only administered intravenously.</p>
</div>
<div class="section level4">
<h4 id="distribution">2.3.2 Distribution<a class="anchor" aria-label="anchor" href="#distribution"></a>
</h4>
<p>Takizawa et al. (<a href="#id_5-references">Takizawa 2005</a>)
published a fu in humans to be 0.024. Mazoit et al. (<a href="#id_5-references">Mazoit 1999</a>) reported that propofol binds to
almost exclusively to serum albumin as plasma protein, which is built-in
as such in the PBPK model.</p>
<p>After testing the available organ-plasma partition coefficient and
cell permeability calculation methods built in PK-Sim, observed clinical
data was best described by choosing the partition coefficient
calculation and cell permeability calculation by PK-Sim standard.
Specific organ permeability normalized to surface area was automatically
calculated by PK-Sim.</p>
</div>
<div class="section level4">
<h4 id="metabolism-and-elimination">2.3.3 Metabolism and Elimination<a class="anchor" aria-label="anchor" href="#metabolism-and-elimination"></a>
</h4>
<p>Propofol undergoes fast biotransformation to different
metabolites.(<a href="#id_5-references">Restrepo 2009</a>) <em>In
vitro</em> studies show that particularly the UGT1A9 (<a href="#id_5-references">Court 2005</a>) is involved, followed by CYP2B6
(<a href="#id_5-references">Oda 2001</a>).</p>
<p>Al-Jahdari et al. (<a href="#id_5-references">Al-Jahdari 2006</a>)
investigated the contribution of the liver and kidneys to propofol
metabolism in humans using an <em>in vitro–in vivo</em> scale up
approach. Human kidney and liver microsomal incubations confirmed the
dominant role of UGT metabolism for propofol. Propofol was in particular
metabolized by UGT1A9 and CYP2B6. The apparent arithmetic mean unbound
K<sub>m</sub> (K<sub>m,u</sub>) values in the liver for the
glucuronidation and hydroxylation of propofol by UGT1A9 and CYP2B6 were
0.12 (standard deviation (SD): 0.072) and 0.0072 (SD: 0.0) mM,
respectively. (<a href="#id_5-references">Al-Jahdari 2006</a>) The
corresponding V<sub>max</sub> values (nmol/min/mg protein) were 2.40
(SD: 0.2) for UGT1A9, and 1.08 (SD: 0.1) for CYP2B6. In the kidney the
K<sub>m,u</sub> and V<sub>max</sub> values for glucuronidation by UGT1A9
were 0.38 (SD: 0.19) mM, and 7.97 (4.5) (nmol/min/mg protein),
respectively. The K<sub>m,u</sub> and V<sub>max</sub> for hydroxylation
were reported to be negligible. (<a href="#id_5-references">Al-Jahdari
2006</a>)</p>
<p>The abundance of proteins in different organs in PK-Sim is calculated
from relative expression values. For each organ, the relative expression
defines the concentration of the protein in whole organ as a fraction of
a defined reference concentration value. The relative gene expressions
for both UGT1A9 and CYP2B6 are derived from reported Reverse
Transcription-Polymerase Chain Reaction (RT-PCR) values by Nishimura et
al. (<a href="#id_5-references">Nishimura 2006</a>)</p>
<p>The reported 25.9 pmol/mg UGT1A9 protein expression level in human
liver microsomes (HLM) by Ohtsuki et al. (<a href="#id_5-references">Ohtsuki 2012</a>) was used to calculate the
reference concentration imputed in PK-Sim. The relationship between age
and human microsomal protein (MPPGL) observed by Barter et al. (<a href="#id_5-references">Barter 2007</a>) is estimated 40 mg/g for a 30
year old individual. As the expression of UGT1A9 is highest in the
kidney and relatively 10% in the liver (<a href="#id_5-references">Nishimura 2006</a>), this resulted in a
reference concentration of 10.36 µmol/L liver tissue for UGT1A9 which is
imputed in PK-Sim. For CYP2B6, which is mainly expressed in the liver,
the reported CYP2B6 protein expression level of 1.56 µmol /L liver
tissue by Rodriguez et al. (<a href="#id_5-references">Rodrigues
1999</a>) is imputed as reference concentration in PK-Sim. The reported
expression level in HLM for CYP2B6 is 39 pmol/mg microsomal protein. (<a href="#id_5-references">Rodrigues 1999</a>)</p>
<p>For the estimation of propofol clearance in PK-Sim, K<sub>cat</sub>
is estimated, which is Vmax/protein expression level in HLM.</p>
<p>Although UGT1A9 expression is highest in the kidney (<a href="#id_5-references">Nishimura 2006</a>), as no measurement results
were available for CYP2B6 mediated hydroxylation in the kidney, the
reported liver <em>in vitro</em> Km,u and Vmax values for UGT1A9 and
CYP2B6 were included in the model. Reported Vmax values were in units
nmol/min/mg protein and thus not directly transferable into the PBPK
model. Therefore, a joint scaling factor f<sub>activity </sub> on the
<em>in vitro</em> K<sub>cat</sub> values was estimated to match observed
<em>in vivo</em> data, and keeping the relative relationship between
those <em>in vitro</em> values (0.89 and 0.53 nmol/min/mg) for UGT1A1
and CYP2B6 fixed according to:</p>
<p>K<sub>cat, UGT1A9</sub> = f<sub>activity </sub> * K<sub>cat,
in-vitro, UGT1A9</sub></p>
<p>K<sub>cat, CYP2B6</sub> = f<sub>activity </sub> * K<sub>cat,
in-vitro, CYP2B6</sub></p>
<p>It is especially important to fix the relative contribution of both
enzymes as a ratio to ensure that, when translating to other populations
(e.g. children where both enzymes may undergo a different ontogeny
pattern, or patients who have differently reduced amounts of UGT1A1 vs
CYP2B6) the relative contributions can be adequately scaled. Note that
the estimated scaling factor f<sub>activity</sub> will be directly
implemented into the final <em>in vivo</em> V<sub>max</sub> values (only
K<sub>cat, UGT1A9</sub> and K<sub>cat, CYP2B6</sub> will be reported in
<a href="#id_3-results-and-discussion">section 3</a>).</p>
<p>Finally, as ~0.3% of the dose is excreted in human urine as unchanged
parent compound, GFR is introduced in the propofol PBPK model.</p>
</div>
</div>
</div>
<div class="section level2">
<h2 id="results-and-discussion">3 Results and Discussion<a id="results-and-discussion"></a><a class="anchor" aria-label="anchor" href="#results-and-discussion"></a>
</h2>
<p>The PBPK model propofol was developed with clinical pharmacokinetic
data after intravenous administration covering a dose range of
1-36mg/kg, including bolus infusion as well as continuous infusion
clinical data.</p>
<p>During the model-fitting, the following parameters were estimated
(all other parameters were fixed to reported values):</p>
<ul>
<li>K<sub>cat</sub> (as unique scaling factor f<sub>activity </sub>, as
described in <a href="#id_233-metabolism-and-elimination">section
2.3.3</a>)</li>
<li>Lipophilicity</li>
</ul>
<p>The mean model fit resulted in an adequate description of all data,
that showed to be highly variable. The reported 2.5 mg/kg bolus infusion
data by Struys et al. (<a href="#id_5-references">Struys 2007</a>) only
contained concentration time profiles over 5 minutes. Nevertheless this
data was included in the analysis, and showed overprediction in the
first 2 minutes by the model, compared to available 1 mg/kg and 2 mg/kg
data reported by Schnider et al. (<a href="#id_5-references">Schnider
1998</a>) that was well described by the propofol PBPK model. This
discrepancy in propofol distribution was assumed to be inter-study
variability related.</p>
<p>Overall, the model results show that the PBPK model of propofol
adequately described the data for all available doses.</p>
<div class="section level3">
<h3 id="propofol-final-input-parameters">3.1 Propofol final input
parameters<a id="final-input-parameters"></a><a class="anchor" aria-label="anchor" href="#propofol-final-input-parameters"></a>
</h3>
<p>The compound parameter values of the final propofol PBPK model are
illustrated below.</p>
<div class="section level4">
<h4 id="compound-propofol">Compound: Propofol<a class="anchor" aria-label="anchor" href="#compound-propofol"></a>
</h4>
<div class="section level5">
<h5 id="parameters">Parameters<a class="anchor" aria-label="anchor" href="#parameters"></a>
</h5>
<table class="table">
<colgroup>
<col width="28%">
<col width="15%">
<col width="43%">
<col width="7%">
<col width="4%">
</colgroup>
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
<th>Alternative</th>
<th>Default</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Solubility at reference pH</td>
<td>124 mg/l</td>
<td>Internet-<a href="https://www.drugbank.ca/drugs/DB00818" class="external-link uri">https://www.drugbank.ca/drugs/DB00818</a>, in water @
25°C</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="even">
<td>Reference pH</td>
<td>7</td>
<td>Internet-<a href="https://www.drugbank.ca/drugs/DB00818" class="external-link uri">https://www.drugbank.ca/drugs/DB00818</a>, in water @
25°C</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Lipophilicity</td>
<td>3.5486243812 Log Units</td>
<td>Parameter Identification-Parameter Identification</td>
<td>Fit</td>
<td>True</td>
</tr>
<tr class="even">
<td>Fraction unbound (plasma, reference value)</td>
<td>0.024</td>
<td>Publication-Drugbank.ca</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Is small molecule</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Molecular weight</td>
<td>178.2707 g/mol</td>
<td>Internet-Drugbank.ca</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>Plasma protein binding partner</td>
<td>Albumin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div>
<div class="section level5">
<h5 id="calculation-methods">Calculation methods<a class="anchor" aria-label="anchor" href="#calculation-methods"></a>
</h5>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Partition coefficients</td>
<td>PK-Sim Standard</td>
</tr>
<tr class="even">
<td>Cellular permeabilities</td>
<td>PK-Sim Standard</td>
</tr>
</tbody>
</table>
</div>
<div class="section level5">
<h5 id="processes">Processes<a class="anchor" aria-label="anchor" href="#processes"></a>
</h5>
<div class="section level6">
<h6 id="systemic-process-glomerular-filtration-gfr">Systemic Process: Glomerular Filtration-GFR<a class="anchor" aria-label="anchor" href="#systemic-process-glomerular-filtration-gfr"></a>
</h6>
<p>Species: Human</p>
<div class="section level7">
<h6 id="parameters-1">Parameters<a class="anchor" aria-label="anchor" href="#parameters-1"></a>
</h6>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th align="right">Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody><tr class="odd">
<td>GFR fraction</td>
<td align="right">1</td>
<td>Publication-Al-Jahdari 2005</td>
</tr></tbody>
</table>
</div>
</div>
<div class="section level6">
<h6 id="metabolizing-enzyme-ugt1a9-al-jahdari-2006-liver">Metabolizing Enzyme: UGT1A9-Al-Jahdari 2006 Liver<a class="anchor" aria-label="anchor" href="#metabolizing-enzyme-ugt1a9-al-jahdari-2006-liver"></a>
</h6>
<p>Molecule: UGT1A9</p>
<p>Metabolite: Propofol glucuronide</p>
<div class="section level7">
<h6 id="parameters-2">Parameters<a class="anchor" aria-label="anchor" href="#parameters-2"></a>
</h6>
<table class="table">
<colgroup>
<col width="31%">
<col width="20%">
<col width="47%">
</colgroup>
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>In vitro Vmax for liver microsomes</td>
<td>2.4 nmol/min/mg mic. protein</td>
<td>Publication-In Vitro-Al-Jahdari 2006 HLM</td>
</tr>
<tr class="even">
<td>Content of CYP proteins in liver microsomes</td>
<td>25.9 pmol/mg mic. protein</td>
<td>Publication-Assumption-Ohtsuki 2012 (UGT1A9)</td>
</tr>
<tr class="odd">
<td>Km</td>
<td>0.12 mM</td>
<td>Publication-In Vitro-Al-Jahdari 2006 HLM (corrected for fu,
mic)</td>
</tr>
<tr class="even">
<td>kcat</td>
<td>471.8406263631 1/min</td>
<td>Parameter Identification</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level6">
<h6 id="metabolizing-enzyme-cyp2b6-cumulative-cyp-action">Metabolizing Enzyme: CYP2B6-Cumulative CYP Action<a class="anchor" aria-label="anchor" href="#metabolizing-enzyme-cyp2b6-cumulative-cyp-action"></a>
</h6>
<p>Molecule: CYP2B6</p>
<div class="section level7">
<h6 id="parameters-3">Parameters<a class="anchor" aria-label="anchor" href="#parameters-3"></a>
</h6>
<table class="table">
<colgroup>
<col width="34%">
<col width="23%">
<col width="42%">
</colgroup>
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>In vitro Vmax for liver microsomes</td>
<td>1.08 nmol/min/mg mic. protein</td>
<td>Publication-In Vitro-Al-Jahdari 2006 HLM</td>
</tr>
<tr class="even">
<td>Content of CYP proteins in liver microsomes</td>
<td>39 pmol/mg mic. protein</td>
<td>Publication-Assumption-Rodriguez 1999 (CYP2B6)</td>
</tr>
<tr class="odd">
<td>Km</td>
<td>0.0072 mM</td>
<td>Publication-Al-Jahdari 2005 HLM (corrected for fu,mic)</td>
</tr>
<tr class="even">
<td>kcat</td>
<td>141.007756417 1/min</td>
<td>Parameter Identification</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
</div>
</div>
<div class="section level3">
<h3 id="propofol-diagnostics-plots">3.2 Propofol Diagnostics Plots<a id="diagnostics-plots"></a><a class="anchor" aria-label="anchor" href="#propofol-diagnostics-plots"></a>
</h3>
<p>Below you find the goodness-of-fit visual diagnostic plots for
propofol PBPK model performance (individually simulated versus observed
plasma concentration and weighted residuals versus time, including the
geometric mean fold error (GMFE)) of all data used for model
building.</p>
<p><a id="table-3-1"></a></p>
<p><strong>Table 3-1: GMFE for Goodness of fit plot for concentration in
plasma.</strong></p>
<table class="table">
<thead><tr class="header">
<th align="left">Group</th>
<th align="left">GMFE</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">Propofol bolus + continuous IV infusion</td>
<td align="left">1.68</td>
</tr>
<tr class="even">
<td align="left">Propofol bolus IV infusion</td>
<td align="left">2.33</td>
</tr>
<tr class="odd">
<td align="left">Propofol continuous IV infusion</td>
<td align="left">1.29</td>
</tr>
<tr class="even">
<td align="left">All</td>
<td align="left">1.57</td>
</tr>
</tbody>
</table>
<p><br><br></p>
<p><a id="figure-3-1"></a></p>
<p><img src="images/006_section_results-and-discussion/008_section_diagnostics-plots/2_gof_plot_predictedVsObserved.png"></p>
<p><strong>Figure 3-1: Goodness of fit plot for concentration in
plasma.</strong></p>
<p><br><br></p>
<p><a id="figure-3-2"></a></p>
<p><img src="images/006_section_results-and-discussion/008_section_diagnostics-plots/3_gof_plot_residualsOverTime.png"></p>
<p><strong>Figure 3-2: Goodness of fit plot for concentration in
plasma.</strong></p>
<p><br><br></p>
</div>
<div class="section level3">
<h3 id="propofol-concentration-time-profiles">3.3 Propofol Concentration-Time
profiles<a id="ct-profiles-model-building"></a><a class="anchor" aria-label="anchor" href="#propofol-concentration-time-profiles"></a>
</h3>
<p>Simulated versus observed plasma concentration-time profiles of all
data are listed below.</p>
<p><a id="figure-3-3"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/1_time_profile_plot_Propofol_Gepts_1987_12mg_kg.png"></p>
<p><strong>Figure 3-3: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-4"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/2_time_profile_plot_Propofol_Gepts_1987_12mg_kg.png"></p>
<p><strong>Figure 3-4: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-5"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/3_time_profile_plot_Propofol_Gepts_1987_18mg_kg.png"></p>
<p><strong>Figure 3-5: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-6"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/4_time_profile_plot_Propofol_Gepts_1987_18mg_kg.png"></p>
<p><strong>Figure 3-6: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-7"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/5_time_profile_plot_Propofol_Gepts_1987_36mg_kg.png"></p>
<p><strong>Figure 3-7: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-8"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/6_time_profile_plot_Propofol_Gepts_1987_36mg_kg.png"></p>
<p><strong>Figure 3-8: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-9"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/7_time_profile_plot_Propofol_Gepts_1987_6mg_kg.png"></p>
<p><strong>Figure 3-9: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-10"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/8_time_profile_plot_Propofol_Gepts_1987_6mg_kg.png"></p>
<p><strong>Figure 3-10: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-11"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/9_time_profile_plot_Propofol_Schnider_1998_1mg_25ug.png"></p>
<p><strong>Figure 3-11: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-12"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/10_time_profile_plot_Propofol_Schnider_1998_1mg_25ug.png"></p>
<p><strong>Figure 3-12: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-13"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/11_time_profile_plot_Propofol_Schnider_1998_1mg_50ug.png"></p>
<p><strong>Figure 3-13: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-14"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/12_time_profile_plot_Propofol_Schnider_1998_1mg_50ug.png"></p>
<p><strong>Figure 3-14: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-15"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/13_time_profile_plot_Propofol_Schnider_1998_2mg_25ug.png"></p>
<p><strong>Figure 3-15: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-16"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/14_time_profile_plot_Propofol_Schnider_1998_2mg_25ug.png"></p>
<p><strong>Figure 3-16: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-17"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/15_time_profile_plot_Propofol_Schnider_1998_2mg_50ug.png"></p>
<p><strong>Figure 3-17: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-18"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/16_time_profile_plot_Propofol_Schnider_1998_2mg_50ug.png"></p>
<p><strong>Figure 3-18: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-19"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/17_time_profile_plot_Propofol_Schnider_1998_2mg_100ug.png"></p>
<p><strong>Figure 3-19: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-20"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/18_time_profile_plot_Propofol_Schnider_1998_2mg_100ug.png"></p>
<p><strong>Figure 3-20: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-21"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/19_time_profile_plot_Propofol_Schnider_1998_2mg_200ug.png"></p>
<p><strong>Figure 3-21: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-22"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/20_time_profile_plot_Propofol_Schnider_1998_2mg_200ug.png"></p>
<p><strong>Figure 3-22: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-23"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/21_time_profile_plot_Propofol_Struys_2007_Bolus_Study.png"></p>
<p><strong>Figure 3-23: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-24"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles-model-building/22_time_profile_plot_Propofol_Struys_2007_Bolus_Study.png"></p>
<p><strong>Figure 3-24: Time Profile Analysis 1</strong></p>
<p><br><br></p>
</div>
</div>
<div class="section level2">
<h2 id="conclusion">4 Conclusion<a id="conclusion"></a><a class="anchor" aria-label="anchor" href="#conclusion"></a>
</h2>
<p>The final propofol PBPK model applies metabolism by UGT1A9, CYP2B6
and glomerular filtration and adequately describes the pharmacokinetics
of propofol in adults receiving intravenous bolus and continuous
infusion of propofol ranging from 1 mg/kg to 36 mg/kg.</p>
<p>This model could be applied for the investigation of drug-drug
interactions (DDI), and translation to special populations such as
pediatrics with regard to UGT1A1 and CYP2B6 metabolism.</p>
</div>
<div class="section level2">
<h2 id="references">5 References<a id="references"></a><a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<p><strong>Al-Jahdari 2006</strong> Al-Jahdari WS, Yamamoto K, Hiraoka
H, Nakamura K, Goto F, Horiuchi R. Prediction of total propofol
clearance based on enzyme activities in microsomes from human kidney and
liver. Eur J Clin Pharmacol. 2006 Jul;62(7):527-33. doi:
10.1007/s00228-006-0130-2. Epub 2006 Jun 9.</p>
<p><strong>Barter 2007</strong> Barter ZE, Bayliss MK, Beaune PH, Boobis
AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen
OR, Tucker GR, Rostami-Hodjegan A. Scaling factors for the extrapolation
of in vivo metabolic drug clearance from in vitro data: reaching a
consensus on values of human microsomal protein and hepatocellularity
per gram of liver.Curr Drug Metab. 2007 Jan;8(1):33-45. doi:
10.2174/138920007779315053.</p>
<p><strong>Court 2005</strong> Court M, Isoform‐Selective Probe
Substrates for <em>In Vitro</em> Studies of Human
UDP‐Glucuronosyltransferases. Methods Enzymol. 2005;400:104-16. doi:
10.1016/S0076-6879(05)00007-8.</p>
<p><strong>Drugbank.ca</strong> (<a href="https://www.drugbank.ca/drugs/DB00818" class="external-link uri">https://www.drugbank.ca/drugs/DB00818</a>)</p>
<p><strong>Gepts 1987</strong> Gepts E, Camu F, Cockshott ID, Douglas
EJ. Disposition of propofol administered as constant rate intravenous
infusions in humans. Anesth Analg. 1987 Dec;66(12):1256-63.</p>
<p><strong>Kuepfer 2016</strong> Kuepfer L, Niederalt C, Wendl T,
Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D.
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT
Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi:
10.1002/psp4.12134. Epub 2016 Oct 19.</p>
<p><strong>Mazoit 1999</strong> Mazoit JX, Samii K. Binding of propofol
to blood components: implications for pharmacokinetics and for
pharmacodynamics. Br J Clin Pharmacol, 47 (1999), pp. 35-42.</p>
<p><strong>Nishimura 2006</strong> Nishimura M and Naito S.
Tissue-specific mRNA expression profiles of human phase I metabolizing
enzymes except for cytochrome P450 and phase II metabolizing enzymes.
Drug Metab Pharmacokinet. 21(5). 357-74. 2006.</p>
<p><strong>Oda 2001</strong> Oda Y, Hamaoka N, Hiroi T, Imaoka S, Hase
I, Tanaka K, Funae Y, Ishizaki T, Asada A. Involvement of human liver
cytochrome P4502B6 in the metabolism of propofol. Br J Clin Pharmacol.
2001 Mar; 51(3): 281–285. doi: 10.1046/j.1365-2125.2001.00344.x</p>
<p><strong>Ohtsuki 2012</strong> Ohtsuki S, Schaefer O, Kawakami H,
Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W,
Ludwig-Schwellinger E, Ebner T, Terasaki T. Simultaneous absolute
protein quantification of transporters, cytochromes P450, and
UDP-glucuronosyltransferases as a novel approach for the
characterization of individual human liver: comparison with mRNA levels
and activities. Drug Metab Dispos. 2012 Jan;40(1):83-92. doi:
10.1124/dmd.111.042259.</p>
<p><strong>PK-Sim Ontogeny Database Version 7.3</strong> (<a href="https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf" class="external-link uri">https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf</a>)</p>
<p><strong>Restrepo 2009</strong> Restrepo JG, Garcia-Martín E, Martínez
C, Agúndez JAG. Polymorphic drug metabolism in anaesthesia. Curr Drug
Metab. 2009 Mar;10(3):236-46. doi: 10.2174/138920009787846305.</p>
<p><strong>Rodrigues 1999</strong> Rodrigues AD. Integrated cytochrome
P450 reaction phenotyping: attempting to bridge the gap between
cDNA-expressed cytochromes P450 and native human liver microsomes.
Biochem Pharmacol. 465-80. 57 (5). 1999.</p>
<p><strong>Schlender 2016</strong> Schlender JF, Meyer M, Thelen K,
Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body
Physiologically Based Pharmacokinetic Approach to Assess the
Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet.
2016 Dec;55(12):1573-1589.</p>
<p><strong>Schnider 1998</strong> Schnider TW, Minto CF, Gambus PL,
Andresen C, Goodale DB, Shafer SL, Youngs EJ. Anesthesiology. 1998
May;88(5):1170-82. doi: 10.1097/00000542-199805000-00006.</p>
<p><strong>Struys 2007</strong> Struys MMRF, Coppens MJ, De Neve N,
Mortier EP, Doufas AG, Van Bocxlaer JFP, Shafer SL. Anesthesiology. 2007
Sep;107(3):386-96. doi: 10.1097/01.anes.0000278902.15505.f8.</p>
<p><strong>Takizawa 2005</strong> Takizawa D, Hiraoka H, Goto F,
Yamamoto K, Horiuchi R. Human kidneys play an important role in the
elimination of propofol. Anesthesiology. 2005 Feb;102(2):327-30. doi:
10.1097/00000542-200502000-00014.</p>
</div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p>Developed by Pierre Chelle.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.2.</p>
</div>

    </footer>
</div>





  </body>
</html>
